Ankle-branch index and HIV: The role of antiretrovirals

HIV Medicine

Volumn 10, Issue 1, 2009, Pages 1-5

  Olalla, Julián ^a   Salas, D ^a   Del Arco, A ^a   De La Torre, J ^a   Prada, J L ^a   Machin Hamalainen S ^b   Garcia Alegria J ^a,c  

^a HOSPITAL COSTA DEL SOL   (Spain)

^b CS General Ricardos   (Spain)

^c CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

Author keywords

Ankle branch index; HAART; HIV; Protease inhibitors; Vascular risk

Indexed keywords

ABACAVIR; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; ZALCITABINE; ZIDOVUDINE;

ADULT; ANKLE BRACHIAL INDEX; ARTICLE; CARDIOVASCULAR RISK; CD4 LYMPHOCYTE COUNT; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL; SMOKING; TREATMENT DURATION;

ADULT; ANKLE; ANKLE BRACHIAL INDEX; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOOD PRESSURE; BRACHIAL ARTERY; DYSLIPIDEMIAS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; PERIPHERAL VASCULAR DISEASES; RISK ASSESSMENT;

EID: 58149188131     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00638.x     Document Type: Article

References (32)

1. Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-860.
2. Lima VD, Hogg RS, Harrigan PR et al. Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS 2007; 21: 685-692.
3. 3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007; 46: 72-77.
4. El Sadr WM, Lundgren JD, Neaton JD et al. CD4 count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2283-2296.
5. Friis-Moller N, Sabin CA, Weber R et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003.
6. Friis-Moller N, Reiss P, Sabin CA et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723-1735.
7. Kannel WB, Giordano M. Long-term cardiovascular risk with protease inhibitors and management of the dyslipidemia. Am J Cardiol 2004; 94: 901-906.
8. Friis-Moller N, Weber R, Reiss P et al. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD Study. AIDS 2003; 17: 1179-1193.
9. Mulligan K, Grunfeld C, Tai VW et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000; 23: 35-43.
10. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000; 275: 20251-20254.
11. Stein JH, Klein MA, Bellehumeur JL et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001; 104: 257-262.
12. Howard AA, Lo Y, Floris-Moore M et al. Hepatitis C virus infection is associated with insulin resistance among older adults with or at risk of HIV infection. AIDS 2007; 21: 633-641.
13. Jain MK, Aragaki C, Fischbach L et al. Hepatitis C is associated with type 2 diabetes mellitus in HIV-infected persons without traditional risk factors. HIV Med 2007; 8: 491-497.
14. Rose H, Woolley I, Hoy J et al. HIV infection and high-density lipoprotein: The effect of the disease vs. the effect of treatment. Metabolism 2006; 55: 90-95.
15. Khovidhunkit W, Kim MS, Memon RA et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: Mechanisms and consequences to the host. J Lipid Res 2004; 45: 1169-1196.
16. McKenna M, Wolfson S, Kuller L. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. Atherosclerosis 1991; 87: 119-128.
17. Newman AB, Siscovick DS, Manolio TA et al. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group. Circulation 1993; 88: 837-845.
18. Sharma A, Holman S, Pitts R et al. Peripheral arterial disease in HIV-infected and uninfected women. HIV Med 2007; 8: 555-560.
19. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome - a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 2006; 23: 469-480.
20. Hirsch AT, Haskal ZV, Hertzer NR et al. Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
21. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001; 344: 1608-1621.
22. Hirsch AT, Haskal ZJ, Hertzer NR et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): A collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113: E463-e654.
23. Programme of Nutrition, Family and Reproductive Health. Obesity. Preventing and Managing the Global Epidemic. Report of a WHO Consultation on Obesity, Geneva, 3-5 June 1997. Geneva: WHO, 1998.
24. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
25. Zhong DS, Lu XH, Conklin BS et al. HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells. Arterioscler Thromb Vasc Biol 2002; 22: 1560-1566.
26. Noor MA, Flint OP, Maa JF, Parker RA. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS 2006; 20: 1813-1821.
27. Schambelan M, Benson CA, Carr A et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: Recommendations of an International AIDS Society-USA Panel. J Acquir Immune Defic Syndr 2002; 31: 257-275.
28. Solages A, Vita JA, Thornton DJ et al. Endothelial function in HIV-infected persons. Clin Infect Dis 2006; 42: 1325-1332.
29. Hsue PY, Lo JC, Franklin A et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004; 109: 1603-1608.
30. Johnsen S, Dolan SE, Fitch KV et al. Carotid intimal medial thickness in human immunodeficiency virus-infected women: Effects of protease inhibitor use, cardiac risk factors, and the metabolic syndrome. J Clin Endocrinol Metab 2006; 91: 4916-4924.
31. Bonfanti P, Giannattasio C, Ricci E et al. HIV and metabolic syndrome: A comparison with the general population. J Acquir Immune Defic Syndr 2007; 45: 426-431.
32. Vogt MT, Cauley JA, Newman AB et al. Decreased ankle/arm blood pressure index and mortality in elderly women. JAMA 1993; 270: 465-469.